During the next 40 years, it is anticipated that there will be an epidemic of dementia worldwide, with a 3- to 4-fold increase in the number of prevalent cases owing to longer life expectancies and demographic changes.
1 Current treatments provide some symptomatic relief but do not alter the course of the disease,
2 and several therapies that initially appeared promising have recently failed in phase III clinical trials.
3-5 Attention is turning toward identification of preclinical disease and development of treatments to prevent or delay the onset of dementia
6; however, there is also concern about potential adverse effects of pharmacological treatment in individuals who may never become symptomatic. Behavioral interventions offer a potential strategy to prevent or delay dementia onset with minimal adverse effects in asymptomatic individuals.